Delox Air - Continuous air bio-decontamination compatible with human presence

Introduction

We learned from the pandemic that air quality is essential for people’s health. Current technologies did not effectively manage infectious diseases propagated by aerosol suspensions of pathogens, leading to the need for social distancing and dramatically impacting the economy and people’s mental health. The challenge is not only cleaning the space but keeping people safe and free from microorganisms’ exposure without harming them with harsh chemicals.

Delox AIR Solution

Delox AIR solution will change the paradigm of bio-decontamination of airborne pathogens in occupied spaces, a disruptive factor in the market. Based on our proprietary dryVHP, Delox AIR can kill microorganisms in the air with 99.99% efficacy, ensuring 100% human safety and consuming up to 20% less energy than current systems. Delox AIR can be readily integrated into any HVAC systems for continuous air purification.

Market Overview

Delox AIR is part of the air purification market. We are targeting the commercial applications that capture the largest market (≈70% in 2021), accounting for €15.0 B by 2030. We will first target settings characterised by:

1. High occupancy density
2. Presence of vulnerable individuals
3. Elevated risk of pathogen spread

These settings include nursing homes, hospitals, office spaces, and educational and governmental buildings.

Business Model

Our business model (B2B) is based on indirect sales through distributors already working in the sector that will easily reach HVAC consultants/contractors (customers) designing and delivering a turnkey HVAC system for the end-user.

Funding Request

We request EIC funding to complete the development of our system and validate it in three different types of closed environments. Our solution addresses the EIC Challenge of “Aerosol Decontamination for Pandemic Management,” satisfying the unmet need of facilitating social interaction and preventing disease spread.